parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in corticotrophs	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12455

receipt 12463: TOX2 in dopamine neurons, braak

power: full sample -0.23 (p 0.360, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.355, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
skeptic: leave-one-out range -0.38 to -0.14, sign flips 0; without severely affected donors -0.23 (p 0.360, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TOX2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12462: TOX2 in oligodendrocytes, braak

power: full sample -0.11 (p 0.677, n 18), 95% CI -0.55 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.05 (p 0.854, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.29 (p 0.246, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.02, sign flips 3; without severely affected donors -0.11 (p 0.677, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TOX2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts